AL Amyloidosis: A Rare Blood Disorder with Multi-Organ Complications

CME: 1.0

Target Audience

The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.

Statement of Need/Program Overview

The wide range of symptoms for amyloidosis that overlap with other conditions often lead to diagnosis and treatment delays, and life-threatening organ damage. The recent approval of the first specific therapy for amyloidosis is changing the treatment landscape, creating a need for clinicians to stay abreast of new findings on the efficacy and safety of traditional and new treatments.

Join expert hematology/oncology faculty to review the variable clinical presentations of amyloidosis to ensure an earlier, accurate diagnosis. Expert panelists will also discuss the recent approval of daratumumab and hyaluronidase-fihj, a new treatment option for patients with amyloidosis. Clinicians will learn how to incorporate a higher index of suspicion and clinical data into patient care to optimize clinical outcomes and patient quality of life.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Review the need for early and accurate diagnosis of amyloidosis to allow timely treatment and prevent life-threatening organ damage
  • Identify patients with amyloidosis who would benefit from targeted therapy
  • Evaluate data on efficacy and safety of current treatments and new treatment options for amyloidosis
  • Implement effective strategies for management of individual patients with amyloidosis to improve clinical outcomes and patient’s quality of life

Post a comment to this article